Key Points
- Liquidia director Stephen Bloch sold 145,954 shares on June 10 at an average price of $65.58, generating about $9.57 million in proceeds. The sale reduced his ownership by 9.33%, though he still holds over 1.4 million shares.
- Liquidia has been performing strongly operationally, posting quarterly earnings of $0.52 per share versus the $0.41 estimate and revenue of $132.87 million, far above expectations. Revenue also surged 4,187.1% year over year.
- Analyst sentiment is mixed but generally positive, with three Strong Buy ratings, five Buy ratings, and two Sell ratings. The stock’s consensus price target is $60.29, below its recent trading price of $71.23.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Stephen Bloch sold 145,954 shares of the business's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $65.58, for a total value of $9,571,663.32. Following the sale, the director owned 1,418,453 shares in the company, valued at approximately $93,022,147.74. This trade represents a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Liquidia Stock Performance
NASDAQ:LQDA opened at $71.23 on Friday. The stock has a market cap of $6.33 billion, a P/E ratio of 508.82 and a beta of 0.58. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The stock's 50-day moving average is $49.85 and its 200-day moving average is $40.89. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $72.71.
Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analysts' expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia's revenue for the quarter was up 4187.1% on a year-over-year basis. Equities research analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current year.
Institutional Trading of Liquidia
Institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia in the fourth quarter valued at approximately $25,000. NewEdge Advisors LLC bought a new stake in Liquidia in the second quarter valued at approximately $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Liquidia in the third quarter valued at approximately $30,000. FNY Investment Advisers LLC bought a new stake in Liquidia in the third quarter valued at approximately $34,000. Finally, Covestor Ltd boosted its holdings in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company's stock valued at $42,000 after acquiring an additional 359 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on LQDA shares. Zacks Research upgraded Liquidia from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 5th. Lifesci Capital upgraded Liquidia to a "strong-buy" rating in a report on Thursday, March 5th. Raymond James Financial restated a "strong-buy" rating and set a $68.00 price target on shares of Liquidia in a report on Thursday, June 4th. BTIG Research boosted their price target on Liquidia from $50.00 to $59.00 and gave the stock a "buy" rating in a report on Monday, May 11th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Liquidia in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $60.29.
Read Our Latest Stock Report on Liquidia
About Liquidia
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
